Delineating parameters of iron overload in MDS patients treated with deferasirox

Leukemia Research

Volumn 34, Issue 12, 2010, Pages 1556-1557

  Leitch, Heather A ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; AZACITIDINE; DEFERASIROX; FERRITIN; IRON; LENALIDOMIDE; TRANSFERRIN;

ANEMIA; CARDIOTOXICITY; CAUSE OF DEATH; COMORBIDITY; CONGESTIVE HEART FAILURE; DRUG TOLERABILITY; EDITORIAL; ERYTHROCYTE TRANSFUSION; HUMAN; IRON BLOOD LEVEL; IRON CHELATION; IRON OVERLOAD; MYELODYSPLASTIC SYNDROME; OXIDATIVE STRESS; PRIORITY JOURNAL; QUALITY OF LIFE; SURVIVAL; THALASSEMIA MAJOR;

AGED; AGED, 80 AND OVER; BENZOIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROCYTE TRANSFUSION; FEMALE; FERRITINS; HUMANS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; LIVER; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROSPECTIVE STUDIES; TRIAZOLES;

EID: 78149360388     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.06.032     Document Type: Editorial

References (13)

1. Olivieri N.F., Brittenham G.M. Iron-chelating therapy and the treatment of thalassemia. Blood 1997, 89(3):739-761.
2. Malcovati L., Della Porta M.G., Cazzola M. Predicting survival and leukemic evolution in patients with myelodysplastic syndrome. Haematologica 2006, 91(12):1588-1590.
3. Malcovati L., Porta M.G., Pascutto C., Invernizzi R., Boni M., Travaglino E., et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005, 23(30):7594-7603.
4. Leitch H.A., Leger C.S., Goodman T.A., Wong K.K., Wong D.H.C., Ramadan K.M., et al. Improved survival in patients with myelodysplastic syndrome receiving iron chelation therapy. Clin Leuk 2008, 2(3):205-211.
5. Rose C., Brechignac S., Vassilief D., Pascal L., Stamatoullas A., Guerci A., et al. Does iron chelation therapy improve suvival in regularly transfused lower risk MDS patients? A multicenter study by the GFM. Leuk Res 2010, 34(7):864-870.
6. Fox F., Kundgen A., Nachtkamp K., Strupp C., Haas R., Germing U., et al. Matched-pair analysis of 186 MDS patients receiving iron chelation therapy or transfusion therapy only. Blood 2009, 114(22):694a.
7. Di Tucci A.A., Matta G., Deplano S., Gabbas A., Depau C., Derudas D., et al. Myocardial iron overload assessment by T2* magnetic resonance imaging in adult transfusion dependent patients with acquired anemias. Haematologica 2008, 93(9):1385-1388.
8. Gattermann N., Finelli C., Porta M.D., Fenaux P., Ganser A., Guerci-Bresler A., et al. Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: results from the large 1-year EPIC study. Leuk Res 2010, 34(9):1143-1150.
9. Jensen P.D., Heickendorff L., Pedersen B., Bendix-Hansen K., Jensen F.T., Christensen T., et al. The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. Br J Haematol 1996, 94(2):288-299.
10. Hellstrom-Lindberg E., Gulbrandsen N., Lindberg G., Ahlgren T., Dahl I.M., Dybedal I., et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin+granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 2003, 120(6):1037-1046.
11. Jensen P.D., Jensen F.T., Christensen T., Nielsen J.L., Ellegaard J. Relationship between hepatocellular injury and transfusional iron overload prior to and during iron chelation with desferrioxamine: a study in adult patients with acquired anemias. Blood 2003, 101(1):91-96.
12. Pullarkat V. Objectives of iron chelation therapy in myelodysplastic syndromes: more than meets the eye?. Blood 2009, 114(26):5251-5255.
13. Greenberg P.L., Koller C.A., Cabantchik Z.I., Warsi G., Glynos T., Paley C., Schiffer C. Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes. Leuk Res 2010, 34(12):1560-1565.